Fractional Flow Reserve Computed Tomography Market Is Valued At US$ 56.2 Million In 2023.

According to a new Fact.MR industry analysis, the global fractional flow reserve computed tomography (FFRCT) market is expected to surge from a valuation of US$ 43.5 million in 2023 to US$ 1.2 billion by 2033, expanding at a CAGR of 35.7% over the decade. FFRCT is a relatively new technique, and currently, only one approved product is available in the market. The market contributed 0.2% share in terms of value to the US$ 23.7 billion global diagnostic imaging devices market in 2022.

FFR-CT, a non-invasive imaging technique, combines computed tomography (CT) with computational fluid dynamics to assess blood flow in coronary arteries. It has emerged as a valuable tool for diagnosing and managing coronary artery disease (CAD), as it provides clinicians with critical information on the functional significance of coronary artery blockages. This technology helps avoid unnecessary invasive procedures like coronary angiography by accurately identifying which blockages are hemodynamically significant. The FFR-CT market has been on a growth trajectory, driven by several factors:

Download a Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=5260 

Key Companies Profiled

• Abbott Laboratories
• Boston Scientific Corp.
• Bracco SpA
• GE Electric Co.
• Heartflow Inc.
• Medtronic PLC
• Terumo Corporation
• B. Braun Melsungen AG
• Siemens AG
• Koninklijke Philips N.V.

• Clinical Utility: FFR-CT offers a more comprehensive assessment of CAD, helping clinicians make informed decisions about patient treatment plans. This technology has the potential to reduce the number of unnecessary invasive procedures and lower healthcare costs.
• Non-Invasive Nature: The non-invasive nature of FFR-CT means reduced patient risk and discomfort compared to traditional coronary angiography, making it a preferred choice for both patients and physicians.
• Advancements in Technology: Ongoing technological advancements have led to improved accuracy and reliability in FFR-CT measurements. These enhancements have broadened the range of applications and increased its adoption in clinical practice.
• Growing Prevalence of CAD: The increasing prevalence of CAD, primarily due to lifestyle factors, has driven the demand for advanced diagnostic tools like FFR-CT.
• Regulatory Support: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have granted approvals and provided guidance for FFR-CT, which has instilled confidence in its clinical use.

Competitive Landscape

At present, the market for fractional flow reserve computed tomography is highly consolidated with limited players. Companies are investing heavily in research initiatives to develop products with advanced diagnostic and imaging technologies.

• In April 2023, HeartFlow, Inc. announced the launch of RoadMap analysis, an AI-enabled solution that helps CT readers recognize coronary stenosis accurately, quickly, and consistently. HeartFlow is now the sole company that provides anatomical and physiological visualization of the coronary arteries to enhance heart disease diagnosis and guide treatment decisions, owing to its enlarged product line.

Industry News:

• Widespread Adoption: FFR-CT has continued to gain acceptance in clinical practice. Many medical institutions and healthcare providers have integrated FFR-CT into their diagnostic protocols, further cementing its role in the management of CAD.
• Enhanced Software and Algorithms: Companies in the FFR-CT market are constantly improving the software and algorithms used in FFR-CT systems. These advancements aim to increase the accuracy and speed of FFR-CT calculations, making the technology more efficient for clinicians.
• Cost-Effectiveness Studies: Researchers and healthcare organizations are increasingly conducting cost-effectiveness studies to demonstrate the economic advantages of FFR-CT. These studies help in justifying the adoption of FFR-CT in clinical settings and reducing the overall cost burden of managing CAD.
• Global Market Growth: The FFR-CT market has expanded globally, with increased adoption in regions outside of North America and Europe. Asia, in particular, has seen a rise in FFR-CT usage as healthcare infrastructure improves and awareness grows.
• Integration with Angiography Systems: Some companies have been working on integrating FFR-CT technology with angiography systems, allowing clinicians to obtain both anatomical and functional information in a single procedure. This can streamline the diagnostic process and improve patient care.
• Guidelines and Recommendations: Medical societies and organizations have updated guidelines and recommendations to include FFR-CT as a diagnostic tool for CAD. These endorsements from authoritative bodies further encourage its use in clinical practice.
• Telemedicine and Remote Consultations: The COVID-19 pandemic accelerated the adoption of telemedicine and remote consultations. FFR-CT, when combined with telehealth solutions, allows for remote assessment of patients, making healthcare more accessible.

The FFR-CT market has evolved significantly, driven by its clinical utility, non-invasive nature, technological advancements, and regulatory support. The technology has gained acceptance in clinical practice and has been subject to continuous improvement in software and algorithms. Moreover, cost-effectiveness studies and global market growth have underscored its importance in the diagnosis and management of CAD. The integration of FFR-CT with angiography systems, telemedicine applications, and ongoing clinical trials will likely contribute to the continued expansion of this market. However, it’s important to note that the information provided here is based on my knowledge as of January 2022, and the FFR-CT market may have experienced further developments and changes since then.